Caplin Point Laboratories’ wholly owned subsidiary company -- Caplin Steriles has been granted final approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Etomidate injection USP, 20 mg/10 ml (2 mg/ml) and 40 mg/20 ml (2 mg/ml) Single-dose vial presentations, a generic therapeutic equivalent version of (RLD), AMIDATE (Etomidate) Injection, of HOSPIRA INC.
Etomidate injection USP had US sales data of approximately $9 million for the 12-month period ending October 2020. Caplin Steriles, has developed and filed 19 ANDAs on its own and with partners, with 11 approvals so far.
Caplin Point Laboratories is engaged mainly in manufacturing a wide range of Ointments, Creams and other External application preparations in addition to the regular segments of pharmaceutical formulations.
